Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kühl, U.
Right arrow Articles by Schultheiss, H.-P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kühl, U.
Right arrow Articles by Schultheiss, H.-P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Diagnosis and treatment of patients with virus induced inflammatory cardiomyopathy

U. Kühl*,1, M. Pauschinger1, M. Noutsias1, J.-F. Kapp2 and H.-P. Schultheiss1

a Department of Cardiology and Pneumonology, Medical Clinic II, Department of Cardiology, University Hospital Benjamin Franklin, Free University of Berlin, Berlin, Germany
b Schering AG, Spezial Therapeutika, Berlin, Germany

* Correspondence: Uwe Kühl, PhD, University Hospital Benjamin Franklin, Department of Cardiology and Pneumonology, Free University of Berlin, Hindenburgdamm 30, D-12200 Berlin, Germany.

Abstract

Chronic viral induced inflammatory cardiomyopathy causes progression of left ventricular dysfunction and is an important cause of dilated cardiomyopathy. Despite of the progress made in heart failure therapy, mortality of dilated cardiomyopathy is still 10% per year. Current heart failure therapy is symptomatic and does not impact on the specific underlying pathogenic mechanisms. Thus, specific treatment strategies that are directed against the underlying pathogenetic causes are required if myocarditis and its sequela, namely inflammatory cardiomyopathy, are to be successfully treated. Because histological and, especially, clinical diagnosis is fraught with numerous problems, an aetiological classification based on histology, immunohistochemistry and molecular biology is favourable, particularly in view of the improvements in methods made in recent years. The combination of these diagnostic techni-ques allows a new classification of dilated cardiomyo-pathy by differentiating the disease entity in subgroups of virus positive and virus negative patients with or without cardiac inflammation. This may not only contribute toward improving our understanding of underlying pathological mechanisms, but ultimately may also assist in developing specific immunomodulatory treatments. Preliminary results from ongoing treatment trials suggest that specific antiviral or anti-inflammatory treatment strategies are successful in patients who have been carefully selected and characterized according to biopsy-based diagnostic criteria.

Key Words: Inflammatory cardiomyopathy • viral heart disease • diagnosis • treatment • immunosuppression • interferon

References

  1. Hosenpud JD, Bennett LE, Keck BM, et al. The Registry of the International Society for Heart and Lung Transplantation: sixteenth official report: 1999. J Heart Lung Transplant. 1999;18:611–626[CrossRef][ISI][Medline]
  2. Elliot P. Diagnosis and management of dilated cardiomyopathy. Eur Heart J. 2000;84:106–112
  3. Michels V, Moll P, Miller, et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med. 1992;326:77–82[Abstract]
  4. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. [news]Circulation. 1996;93:841–842[Free Full Text]
  5. Kuhl U, Noutsias M, Seeberg B, et al. Immunohistological evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopathy. Heart. 1996;75:295–300[Abstract/Free Full Text]
  6. Feldmann AM, McNamara D. Myocarditis. N Engl J Med. 2000;343:1388–1398[Free Full Text]
  7. Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation. 2001;104:1076–1082[Free Full Text]
  8. Baboonian C, Treasure T. Meta-analysis of the association of enteroviruses with human heart disease. Heart. 1997;78:539–543[Abstract/Free Full Text]
  9. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation. 1999;99:1091–10100[Abstract/Free Full Text]
  10. Pauschinger M, Bowles NE, Fuentes-Garcia FJ, et al. Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation. 1999;99:1348–1354[Abstract/Free Full Text]
  11. Badorff C, Noutsias M, Kuhl U, et al. Cell-mediated cytotoxicity in hearts with dilated cardiomyopathy: correlation with interstitial fibrosis and foci of activated T lymphocytes. J Am Coll Cardiol. 1997;29:429–434[Abstract]
  12. Fairweather D, Kaya Z, Shellam GR, et al. From infection to autoimmunity. J Autoimmun. 2001;16:175–186[CrossRef][ISI][Medline]
  13. Noutsias M, Pauschinger M, Schultheiss H, et al. Phenotypic characterization of infiltrates in dilated cardiomyopathy: diagnostic significance of T-lymphocytes and macrophages in inflammatory cardiomyopathy. Med Sci Monit. 2002;8:CR478–CR487[Medline]
  14. Kuhl U, Toussaint H, Ulrich G, Wagner D, Wolff P, Schultheiss HP. Evaluation of immunohistological data for the diagnosis of myocarditis. Schultheiss HP. New concepts of viral heart disease. Berlin, Heidelberg, New York: Springer-Verlag; 1988. p. 325–336
  15. Kuhl U, Noutsias M, Seeberg B, et al. Immunohistological evaluation of myocardial biopsies from patients with dilated cardiomyopathy. J Heart Fail. 1994;9:231–245
  16. Kuhl U, Noutsias M, Seeberg B, et al. Chronic inflammation in the myocardium of patients with clinically suspected dilated cardiomyopathy. J Card Fail. 1994;1:13–25[CrossRef][Medline]
  17. Noutsias M, Seeberg B, Schultheiss HP, et al. Expression of cell adhesion molecules in dilated cardiomyopathy: evidence for endothelial activation in inflammatory cardiomyopathy. Circulation. 1999;99:2124–2131[Abstract/Free Full Text]
  18. Kuhl U, Seeberg B, Schultheiss HP, et al. Immunohistological characterization of infiltrating lymphocytes in biopsies of patients with clinically suspected dilated cardiomyopathy. Eur Heart J. 1994;15:62–67
  19. Noutsias M, Pauschinger M, Ostermann K, et al. Digital image analysis system for the quantification of infiltrates and cell adhesion molecules in inflammatory cardiomyopathy. Med Sci Monit. 2002;8:MT59–MT71[Medline]
  20. Noutsias M, Fechner H, de Jonge H, et al. Human coxsackie-adenovirus receptor is colocalized with integrins alpha(v)beta(3) and alpha(v)beta(5) on the cardiomyocyte sarcolemma and upregulated in dilated cardiomyopathy: implications for cardiotropic viral infections. Circulation. 2001;104:275–280[Abstract/Free Full Text]
  21. Pauschinger M, Doerner A, Kuehl U, et al. Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation. 1999;99:889–895[Abstract/Free Full Text]
  22. Schultheiss HP, Kühl U. Cardiomyopathies and specific heart muscle diseases. Poole-Wilson PA, Coluci C, Massie BN, Chatterje K. Heart failure: scientific principles and clinical practice. New York: Churchill Livingstone; 1997. p. 423–438
  23. Schultheiss HP, Pauschinger M, Dörner A, et al. Inflammatory cardiomyopathy. [in German] Ganten D, Ruckpaul K. Handbuch der molekularen Medizin. Herz-Kreislauf-Erkrankungen. Berlin, Heidelberg: Springer-Verlag; 1998. p. 111–146
  24. Dec GW Jr., Palacios IF, Fallon JT, et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Engl J Med. 1985;312:885–890[Abstract]
  25. Grogan M, Redfield MM, Bailey KR, et al. Long-term outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1995;26:80–84[Abstract]
  26. McCarthy RE, Boehmer JP, Hruban RH, et al. Long-terme outcome of fulminant myocarditis as compared with acute (non-fulminant) myocarditis. N Engl J Med. 2000;342:734–735[Free Full Text]
  27. Kuhl U, Strauer BE, Schultheiss HP. Methylprednisolone in chronic myocarditis. Postgrad Med J. 1994;70:S35–S42
  28. McNamara DM, Rosenblum WD, Janosko KM, et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation. 1997;95:2476–2478[Abstract/Free Full Text]
  29. Dorffel WV, Wallukat G, Baumann G, et al. Immunoadsorption in dilated cardiomyopathy. Ther Apher. 2000;4:235–238[CrossRef][Medline]
  30. Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;103:220–225[Abstract/Free Full Text]
  31. Staudt A, Schaper F, Stangl V, et al. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation. 2001;103:2681–2686[Abstract/Free Full Text]
  32. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 2001;104:39–45[Abstract/Free Full Text]
  33. Parrillo JE, Cunnion RE, Epstein SE. A prospective, randomized, controlled trial of prednisolon for dilated cardiomyopathy. N Engl J Med. 1989;321:1061–1068[Abstract]
  34. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. 1995;333:269–275[Abstract/Free Full Text]
  35. McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103:2254–2259[Abstract/Free Full Text]
  36. Cunnion RE, Parrillo JE. Immunosuppressive therapy for myocarditis. [letter, comment]N Engl J Med. 1995;333:1713 discussion 1714[Free Full Text]
  37. Hahn EA, Hartz VL, Moon TE, et al. The Myocarditis Treatment Trial: design, methods and patients enrollment. Eur Heart J. 1995;16(suppl O):162–167
  38. Maisch B, Camerini F, Schultheiss HP. Immunosuppressive therapy for myocarditis. [letter, comment]N Engl J Med. 1995;333:1713 discussion 1714

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Crit Care NurseHome page
T. L. Uhl
Viral Myocarditis in Children
Crit. Care Nurse, February 1, 2008; 28(1): 42 - 63.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kühl, U.
Right arrow Articles by Schultheiss, H.-P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kühl, U.
Right arrow Articles by Schultheiss, H.-P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?